View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
June 17, 2021updated 12 Jul 2022 11:06am

LoA Update: Inversago’s Prader-Willi Syndrome trial sees seven-point spike in chances to transition to next stage after Phase I status update

Inversago Pharma’s Phase I asset MRI-1867 for Prader-Willi Syndrome (PWS) saw its Phase Transition Success Rate (PTSR) jump seven points to 70%.

By William Newton

Inversago Pharma’s Phase I asset MRI-1867 for Prader-Willi Syndrome (PWS) saw its Phase Transition Success Rate (PTSR) jump seven points to 70%. The PTSR update occurred on 14 June, on the heels of the Phase I’s ClinicalTrials.gov listing changing the trial’s status to completed on 10 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Montreal, Canada-based Inversago enrolled 40 patients in the placebo-controlled, single-ascending dose Phase I study. On 10 June, the trial’s ClinicalTrials.gov listing was changed to state the Phase I completed on 16 May. PWS, a genetic disorder affecting chromosome 15, can cause short stature and behavioural and intellectual disabilities. MRI-1867 is a cannabinoid receptor type 1 antagonist.

The Phase I update resulted in a modest one-point bump to the drug’s Likelihood of Approval (LoA), which rose to 12%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm and is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena